TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

18 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

12 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

06 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

07 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

12 Sep 2024 18:00:00 By Nasdaq GlobeNewswire

Terns Announces Pricing of Upsized $150.15 Million Public Offering

10 Sep 2024 21:50:00 By Nasdaq GlobeNewswire

Terns Announces Proposed Public Offering

09 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

09 Sep 2024 06:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates

05 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

01 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

29 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation

21 Jun 2024 17:30:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

03 Jun 2024 15:10:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

30 May 2024 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

17 May 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

13 May 2024 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Leadership Changes

08 May 2024 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

07 May 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

03 May 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

29 Apr 2024 15:05:00 By Nasdaq GlobeNewswire